Posted on 8/7/18
Realm Therapeutics to Report First Half 2018 Financial Results
Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company . . .
Posted on 8/7/18
Recro Pharma Reports Second Quarter 2018 Financial Results
MALVERN, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other . . .
Posted on 8/17/18
Interview with Paula Swain, EVP of Human Resources at Incyte Corporation - Part III
Brought to you by Newmark Knight Frank
Posted on 8/14/18
Interview with Paula Swain, EVP of Human Resources at Incyte Corporation - Part II
Brought to you by Newmark Knight Frank
Posted on 8/9/18
Interview with Paula Swain, EVP of Human Resources at Incyte Corporation - Part I
Brought to you by Newmark Knight Frank
Posted on 8/7/18
Why Pfizer Stock Gained 10% in July
What happenedPfizer (NYSE:PFE) stock outpaced the market last month, gaining 10% compared to a 3.6% increase in the S&P 500, according to data provided by S&P . . .
Posted on 8/7/18
ContraVir Pharmaceuticals Provides an Update to Corporate Objectives
EDISON, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the . . .
Posted on 8/6/18
Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Pennsylvania
NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, . . .
Posted on 8/6/18
OncoSec Enters Research Collaboration Agreement with UCLA and Roger S. Lo, M.D., Ph.D.
OncoSec Medical Incorporated (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has entered into a research collaboration agreement with the University of California, Los . . .
Posted on 8/6/18
Krystal Biotech Reports Second Quarter 2018 Financial Results and Provides Corporate Update
PITTSBURGH, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf” topical and intra-dermal treatments for skin diseases, today reported financial . . .
Posted on 8/6/18
Antares Pharma Enters Into Development Agreement With Pfizer
EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has entered into an agreement with Pfizer Inc. to . . .
Posted on 8/6/18
Better Buy: Pfizer Inc. vs. AbbVie Inc.
This year, AbbVie Inc. (NYSE:ABBV) showed us why it's important to stay invested for the long haul. Despite a recent thumping, the stock has delivered a . . .
Posted on 8/5/18
Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center
Salix Pharmaceuticals, a leading specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal (GI) disorders and a wholly owned subsidiary of Bausch Health Companies . . .
Posted on 8/3/18
Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
PHILADELPHIA, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced . . .
Posted on 8/3/18
Agile Therapeutics Reports Second Quarter 2018 Financial Results
PRINCETON, N.J., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and six . . .
Posted on 8/3/18
Aclaris Therapeutics Reports Second Quarter 2018 Financial Results
WAYNE, Pa., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address . . .
Posted on 8/3/18
Better Buy: Johnson & Johnson vs. Pfizer
Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) rank as the biggest of big pharma companies in the United States. Both companies trace their roots back to . . .
Posted on 8/3/18
5 Things You'll Want to Know About Pfizer's Future
Investors liked what they saw with Pfizer's (NYSE:PFE) second-quarter earnings results, announced on Tuesday. Although revenue growth of 4% wasn't anything to get excited about, the . . .
Posted on 8/3/18
Teva Pharmaceutical Industries (TEVA) Q2 2018 Results - Earnings Call Transcript
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Q2 2018 Earnings Call August 2, 2018 8:00 AM ETExecutivesKevin C. Mannix - Teva Pharmaceutical Industries Ltd.Kåre Schultz - Teva Pharmaceutical . . .
Posted on 8/2/18
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to . . .
Posted on 8/2/18
Marinus Pharmaceuticals Provides Business Update
RADNOR, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and . . .
Posted on 8/2/18
Akcea Therapeutics and PTC Therapeutics Collaborate
PTC Therapeutics, Inc. (NASDAQ: PTCT), and Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced a collaboration under which PTC . . .
Posted on 8/2/18
Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
DEVON, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, . . .
Posted on 8/2/18
Merck: Keytruda Remains The Name Of The Game
SummaryMerck continues to see growth, driven by Keytruda.Operating momentum only appears to strengthen as more investors recognise the improved results.Following a recent run higher, I still . . .
Posted on 8/1/18
Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics . . .

